Followers | 145 |
Posts | 27558 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Thursday, April 27, 2017 7:53:16 AM
OMER, ISRAEL--(Marketwired - Apr 27, 2017) - Medigus Ltd. ( NASDAQ : MDGS ) ( TASE : MDGS ), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today announced that the first ten procedures have been performed as the initial phase of the China Food and Drug Administration, or CFDA, multi-center MUSE™ Clinical Study in China.
"The availability of the MUSE™ procedure in China provides patients with a less invasive option for the long-term treatment of GERD," said principal investigator, Yunsheng Yang, Director of Gastroenterology Department Clinical center at 301 Hospital and chairman of Chinese Society of Gastroenterology, The General Hospital of People's Liberation Army in Beijing. "The procedure addresses a new hope and solution between drug therapy and surgical procedures."
Procedures for the clinical study, which will include approximately 62 patients, have begun at four centers across China:
The General Hospital of People's Liberation Army
Renji Hospital of Shanghai
Shanghai General Hospital
Peking University Third Hospital
Procedures are expected to continue through 2017, with results being reported to the CFDA in 2018 as part of the submission for clearance to sell MUSE™ in China.
"This is yet another milestone in our mission to expand the use of MUSE worldwide," said Chris Rowland, CEO of Medigus. "We are looking forward to a successful clinical trial in China, which will lead to higher adoption of MUSE in the East Asian market, which has an increasing prevalence of GERD."
The MUSE system is a single-use flexible transoral stapler that merges the latest advancements in microvisual, ultrasonic and surgical stapling. The device comes equipped with an ultrasonic sight and range finder and a micro ScoutCam™ CMOS camera, which enables a single physician to perform an incisionless transoral fundoplication -- the procedure intended to treat the anatomical cause of gastroesophageal reflux disease (GERD).
For more information about the clinical study or to determine if you are eligible for the trial, patients can directly contact participating medical centers.
About Medigus
Medigus is a medical device company specializing in developing minimally invasive endosurgical tools and highly innovative imaging solutions. They are the pioneer developer of the MUSE™ system, an FDA cleared and CE marked endoscopic device to perform Transoral Fundoplication (TF) for the treatment of GERD (gastroesophageal reflux disease), one of the most common chronic conditions in the world. In 2016, the CMS established the Category I CPT® Code of 43210 for TF procedures, such as the ones performed with MUSE, which establishes reimbursement values for physicians and hospitals. MUSE is gaining adoption in key markets around the world -- it is available in world-leading healthcare institutions in the U.S., Europe and Israel. Medigus is also in the process of obtaining regulatory clearance in China. Medigus is traded on the Nasdaq Capital Market and the TASE (Tel-Aviv Stock Exchange). To learn more about the company's advanced technology, please visit www.medigus.com or www.RefluxHelp.com.
Recent MDGS News
- Xylo Technologies Files its 2023 Annual Report on Form 20-F • GlobeNewswire Inc. • 04/22/2024 08:05:00 PM
- Medigus Announces Corporate Rebranding Changes Name to Xylo Technologies Ltd. to Reflect Core Values of its Business • GlobeNewswire Inc. • 04/09/2024 08:03:00 PM
- Medigus Reaps Success with First Installation of a Wireless Charging System for Automatic Car Parks • GlobeNewswire Inc. • 04/01/2024 11:49:00 AM
- Medigus: Revoltz Initiates on Exclusive Distribution Agreement of $2.7 Million in Revenues and Completes the Production of the First 50 PORTO Micro-Mobility EVs • GlobeNewswire Inc. • 03/27/2024 11:55:00 AM
- Medigus: Charging Robotics Announces Successful Installment of its Wireless Charging System for Automatic Car Parks • GlobeNewswire Inc. • 03/19/2024 01:25:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/07/2024 09:19:48 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/22/2024 12:41:09 PM
- Medigus: ParaZero Ramps Up Partnership with US-Based Autonomous Drone OEM Vayu Aerospace Corporation • GlobeNewswire Inc. • 02/22/2024 12:38:50 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 09:00:18 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/12/2024 09:01:08 PM
- Medigus: Revoltz Opens for Pre-Orders of its Revolutionary Micro Mobility EV • GlobeNewswire Inc. • 01/04/2024 12:45:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/27/2023 01:10:37 PM
- Medigus: Charging Robotics Announces Positive Results in Transferring High Voltage Wireless Electricity Needed for EV Charging • GlobeNewswire Inc. • 12/27/2023 01:10:00 PM
- Medigus: Charging Robotics Targets the $1.8 Billion Automated Parking Market for EV Wireless Charging Solution • GlobeNewswire Inc. • 12/26/2023 12:11:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/21/2023 12:01:20 PM
- Medigus: ParaZero Successfully Completed its Drone Safety Project with a Fortune 500 Leading Automotive Manufacturer • GlobeNewswire Inc. • 12/21/2023 11:59:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/18/2023 01:42:23 PM
- Medigus: Jeffs' Brands Signs a Non-Binding Letter of Intent to Invest in a Remote Wireless Electric Charging Technology Company • GlobeNewswire Inc. • 12/18/2023 01:40:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/14/2023 09:05:16 PM
- Medigus: Jeffs' Brands Signs a Non-Binding Letter of Intent to acquire a 70% in a Laser-based Technology Company Developing Defense Solutions Against Drone-based Visual Systems • GlobeNewswire Inc. • 12/14/2023 09:01:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/22/2023 03:11:27 PM
- Medigus: Charging Robotics to Receive Funding from the Israel Innovation Authority for Piloting its Wireless Charging Solution for Automated Parking System • GlobeNewswire Inc. • 11/22/2023 03:10:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/13/2023 12:47:16 PM
- Medigus: Metagramm to Develop Bubbl, its Most Advanced AI-Powered Writing and Grammar Tool • GlobeNewswire Inc. • 11/13/2023 12:45:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/16/2023 12:00:03 PM
FEATURED Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • Apr 25, 2024 8:52 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM